Sangamo Therapeutics, Inc.
SGMO
$0.15
-$0.02-12.73%
OTC PK
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -89.87% | 2,348.88% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -89.87% | 2,348.88% | |||
| Cost of Revenue | -15.48% | 11.71% | |||
| Gross Profit | -46.01% | 37.56% | |||
| SG&A Expenses | -12.12% | -2.93% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -14.82% | 8.47% | |||
| Operating Income | -27.95% | 29.77% | |||
| Income Before Tax | 18.37% | -8.21% | |||
| Income Tax Expenses | -- | -243.48% | |||
| Earnings from Continuing Operations | 17.17% | -7.13% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 17.17% | -7.13% | |||
| EBIT | -27.95% | 29.77% | |||
| EBITDA | -30.06% | 30.54% | |||
| EPS Basic | 28.16% | 3.48% | |||
| Normalized Basic EPS | -8.52% | 36.48% | |||
| EPS Diluted | 28.16% | 3.48% | |||
| Normalized Diluted EPS | -8.52% | 36.48% | |||
| Average Basic Shares Outstanding | 15.36% | 11.00% | |||
| Average Diluted Shares Outstanding | 15.36% | 11.00% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||